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EFFECTS OF HIV AND DRUGS OF ABUSE ON THE BLOOD-BRAIN BARRIER
Gopika Hari, MaryPeace McRae
Virginia Commonwealth University, School of Pharmacy

METHODS

INTRODUCTION
Despite effective systemic therapy, HIV-1 infection
within the brain results in neuronal degradation
and
neurocognitive
dysfunction.
This
neurocognitive dysfunction is worsened in the
setting of opiate abuse. The central nervous
system (CNS) is protected by the blood-brain
barrier (BBB), a selective barrier regulating the
passage of substances from peripheral circulation
into the CNS. The BBB is composed of
microvascular endothelial cells encased by basal
lamina, pericytes, and perivascular astrocyte
endfeet. Intracellular junctional complexes
comprising of adherens and tight junctions are
located between the endothelial cells and form
tight barrier, preventing traffic of compounds
between cells (paracellular flux). Clinical and in
vitro data suggest that BBB integrity is
compromised in HIV infection, which leads to a
leaky barrier. Brain microvascular endothelial
cells also express efflux transporters that are
responsible for the extrusion of substances from
the brain back into the blood. P-glycoprotein is a
drug efflux transporter involved in the efflux of
many antiretroviral drugs and overexpression of
P-glycoprotein
can
limit
therapeutic
concentrations of substrate drugs within the
brain. Additionally, P-glycoprotein expression
and/or function may be altered in the setting of
HIV infection and in the setting of drug abuse.

Experiment
#1

CONCLUSIONS

Rhodamine-123 Accumulation

In order to study the impact of morphine, a commonly used
opiate drug of abuse, on drug-efflux proteins at the BBB, the
effects of morphine and the HIV-1 protein Tat on P-glycoprotein
Well with cells
function were studied via intracellular accumulation studies.
hCMEC/D3 cells, a human derived brain microvascular
endothelial cell line, were pre-treated for 24h with Tat (100nM),
morphine (500nM), or Tat (100nM) + morphine (500nM). 12Rh123 solution added
well plates with 3 replicates of each treatment group were used.
Accumulation was determined by measuring florescence from
the prototypical P-glycoprotein substrate, rhodamine-123,
Cells washed and florescence measured
following cell lysis.
Experiment
#2

Extracellular space

PGP

Inside of hCMEC/D3 cell
= florescent Rhodamine-123

P-glycoprotein Western Blots

The effects of Tat and morphine on Pgp protein expression
were measured by immunoblot. Gels were run in an
electrophoresis box and protein was transferred to the
membrane using a wet transfer. Blots were then blocked
with milk and probed for both P-glycoprotein and beta-actin
(to provide controls for each sample). C219 (1:200 dilution)
was used for Pgp primary antibody, and anti-beta actin
(1:4000 dilution) was used for beta-actin primary. Both
samples used anti-mouse HRP-linked substrate (1:20000
dilution) for secondary antibodies.
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RESULTS
Finding
#1

Rhodamine-123 Accumulation

Finding
#2

Increase in accumulation of Rhodamine-123
within cells treated with Tat, morphine, and
Tat+morphine treatment groups indicate
decreased ability of P-glycoprotein to efflux
substrates out of the cell. This is
complemented with decreased expression of
the P-glycoprotein protein in endothelial cell
membranes under each of the treatment
groups. Both experiments indicate increased
leakiness of the BBB when exposed to HIV-1
protein and opioids. This has implications in
both determining substances that lead to
increased BBB breakdown and factors that
lead to increased permeability of cells to
antiretroviral therapy drugs.

P-glycoprotein Western Blots

Areas for further study include:
• Analysis of Tat and morphine on other drug
efflux proteins, such as breast cancer
resistance protein (BCRP) and the multidrug
resistance proteins (MRPx).
• Intracellular accumulation of drugs used in
the treatment of HIV ( such as atazanavir or
lopinavir) would allow for analysis of the
impact of P-glycoprotein in efflux of
antiretroviral therapy drugs.
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OBJECTIVES
The purpose of this study was to analyze the
impact of HIV-1 Tat and morphine on Pglycoprotein (Pgp) as a means to study the impact
of substance abuse drugs on drug-efflux proteins
in the BBB. This will be done by:
Analyzing Pgp function through Rhodamine-123
cellular accumulation studies
Analyzing Pgp expression through Western Blots
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